Treatment of HER2+ Breast Cancer: Insights from Experts at Texas Oncology, UT Southwestern Dallas, and UT Health San Antonio - Episode 2

Trastuzumab Deruxtecan Maintenance after First-Line Therapy for HER2+ mBC

, , ,

Joyce O’Shaughnessy, MD, starts a discussion on maintenance therapy with trastuzumab deruxtecan in patient with HER2+ mBC.